Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03979365 · ClinicalTrials.gov registry record · Phase 4
Envarsus XR Compared to Immediate Release Tacrolimus
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 261
- Enrollment target
NCT03979365: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT03979365 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 261 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03979365, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 261 participants
- Enrollment target
Study Summary
The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR®) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR®) report fewer side effects, increased medication compliance and higher scores on quality of life assessments compared to people taking twice daily tacrolimus immediate release.
Interventions
- DRUG Envarsus XR
- DRUG Tacrolimus twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2022-03-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03979365
The ClinicalTrials.gov registry entry for NCT03979365 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Envarsus XR is the first listed.
NCT03979365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03979365 about?
NCT03979365 is a clinical study titled "Envarsus XR Compared to Immediate Release Tacrolimus". The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR®) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR®) report fewer side effects, increased medication compliance and higher scores on quality of...
What is the current status of trial NCT03979365?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 261 participants. The study started on 2019-07-18. Estimated completion is 2022-03-29.
What interventions are being tested in trial NCT03979365?
The interventions under investigation include: Envarsus XR (DRUG), Tacrolimus twice daily (DRUG).
Who is sponsoring clinical trial NCT03979365?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.